Printer Friendly

SYNTEX AND ANTIBIOTICOS, S.p.A. BREAK GROUND FOR NEW FERMENTATION EXTRACTION FACILITY IN ITALY

 PALO ALTO, Calif., Sept. 16 /PRNewswire/ -- Syntex Corp. (NYSE: SYN) announced today that Syntex and Antibioticos, S.p.A. have started construction on a new $20 million fermentation extraction facility near Turin, Italy.
 Syntex and Antibioticos, an Italian pharmaceutical fermentation and chemical manufacturer based in Milan, are jointly developing the plant, which is scheduled for completion at the end of 1994.
 The new facility will extract, from fermentation broth, a key intermediate which will be converted to the active ingredient, mycophenolate mofetil. Mycophenolate mofetil is an immunosuppressant that Syntex is developing for potential use in preventing and treating acute and chronic rejection of an organ graft after transplant. The compound is in Phase III clinical trials. Syntex expects to file a New Drug Application in calendar 1994 for approval to market mycophenolate mofetil in the United States.
 Antibioticos developed the fermentation extraction process for the key intermediate and currently produces the ingredient for Syntex's conversion and use in clinical trials.
 Following fermentation and extraction in Italy, the resulting intermediate is sent to other Syntex facilities for chemical conversion to bulk active ingredient. Syntex and Antibioticos have been working together since July 1990.
 Fermentation compounds each require a unique and dedicated fermentation extraction system, according to Robert Ells, Syntex's corporate group vice president of Pharmaceutical and Chemical Operations and Services. "We are pleased to be working on this important project with Antibioticos, one of the largest and most technically advanced fermentation manufacturers in the world," Ells said.
 "Construction of this facility is a milestone that will help us to bring this significant new Syntex product to market," said Syntex Chairman and Chief Executive Officer Paul Freiman.
 Syntex Corp., a multinational healthcare company with approximately $2 billion in annual sales, discovers, develops, manufactures and markets human and animal pharmaceutical products and medical diagnostic systems.
 Antibioticos, part of the Ferruzzi-Montedison Group, is a multinational producer of pharmaceutical intermediates and third parties' proprietary active compounds, with approximately $320 million in annual sales.
 -0- 9/16/93
 /CONTACT: Nicole Sunahara, 415-855-5052, or Linda Thomas, 415-852-1321, both of Syntex/
 (SYN)


CO: Syntex Corp.; Antibioticos, S.p.A.; Ferruzzi-Montedison Group ST: California IN: MTC SU:

TM -- SJ002 -- 2678 09/16/93 12:14 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 16, 1993
Words:367
Previous Article:R&W BUILDS INTERNATIONAL BANKRUPTCY PRACTICE; SELINDA A. MELNIK JOINS THE FIRM
Next Article:POWERADE TO BECOME OFFICIAL SPORTS DRINK OF GEORGIA TECH
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters